权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Positive Allosteric Modulators as PET Imaging Ligans for mGluR4

作为 mGluR4 PET 成像配体的正变构调节剂

基本信息

批准号：
10224422
负责人：
ANNA-LIISA BROWNELL
金额：
$ 41.48万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-30 至 2022-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10224422
关键词：
Academia Affect Affinity American Antiparkinson Agents Binding Binding Proteins Binding Sites Biological Biological Availability Blood Blood Volume Brain Brain imaging Cell Line Cells Central Nervous System Diseases China Clinical Trials Computer Models Data Development Diagnostic Disease Dopamine Dose Drug Compounding Drug Design Drug Kinetics Equilibrium Evaluation Fluorine Future GRM5 gene Germany Glutamates Goals Health Care Costs Human Image Imaging ligands India Industry International Investigation Investigational New Drug Application Japan Knockout Mice Label Lead Letters Ligands Location Magnetic Resonance Imaging Medical Metabolic Metabolism Modeling Neurodegenerative Disorders Neurons Parkinson Disease Pathology Pathway interactions Penetration Pharmaceutical Preparations Pharmacology Physiological Plasma Positron-Emission Tomography Primates Process Property Publications Publishing Radiation Dose Unit Radiolabeled Rattus Research Resolution Series Site Structure Synapses System Testing Therapeutic Therapeutic Uses Time Toxicology Tracer Transformed Cell Line Treatment Cost Work base computational chemistry cross reactivity drug development drug discovery gamma-Aminobutyric Acid imaging study in vivo in vivo imaging interest kinetic model metabotropic glutamate receptor 4 nervous system disorder neural circuit neurotransmission neurotransmitter release novel therapeutic intervention positive allosteric modulator pre-clinical presynaptic presynaptic neurons radiotracer receptor receptor function theories therapeutic target usability

项目摘要

ABSTRACT: Half a million Americans suffer from Parkinson’s disease (PD) and the incurring health cost is $6 billion in a year. There are several other neurological disorders with extremely high cost for treatment, but in this context the focus is on the disorders, which have strong connection to glutamate neurotransmission. Presynaptic location of mGlu4 makes them important contributors for glutamate neurotransmission since glutamate as well as dopamine is released from the presynaptic site of the neuron and activation of mGlu4 can inhibit the release of neurotransmitters such as glutamate and GABA and thus balance neurotransmission through direct and indirect pathways in PD. Several recent publications propose especially mGlu4 as therapeutic target for different neurological diseases including PD. We have extensively investigated positive allosteric modulators (PAMs) as PET imaging ligands for mGlu4. We investigated also biological activity of the developed compounds using pharmacological MRI approaches. These studies opened a new way to characterize compounds and explore their usability for therapeutic purposes. We have synthetized 32 different compounds based on two different chemo-types of the mGlu4 PAMs. Six of these compounds have been characterized with in vivo studies as PET imaging ligands for mGlu4. The main limitation in our developed ligands has been fast washout and metabolism, even though binding affinities have been decent. We also developed specific cell lines to express mGlu4 and the cell studies have been fundamental in ligand characterization to determine the structure-affinity relationship (SAR) of our experimental PAMs and determine co-operative relationship between endogenous glutamate binding to orthosteric binding sites and affinity of allosteric modulators. These approaches are radically different from classical approach in which orthosteric ligands compete with endogenous ligands at the same binding site. Based on the pioneering work and worldwide interest we are looking for to develop especially fluorine-18 labeled positive allosteric imaging ligands for mGlu4 allowing medical applications and distribution of the ligands. Precisely, in Aim 1 we are proposing to synthesize two F-18 labeled lead compounds from the N- phenylpicolinamide- and thiazolopyrazole-based mGlu4 PAMs to study their imaging efficacy, Bmax, selectivity, brain penetration, pharmacokinetics, metabolic stability and other properties. In Aim 2 we will synthesize new series of eight fluorine-containing N-phenylpicolinamide derivatives and twelve fluorine- containing thiazolopyrazole derivatives for SAR analyses. This effort will be supported by computational chemistry. Two best compounds will be selected for the development as PET imaging ligands for mGlu4. In Aim 3 we will conduct in vivo characterization of these ligands using mGlu4 knockout mice, rat and primate models with an ultimate goal to validate the best compound for human studies and obtain IND approval.

摘要：50万美国人患有帕金森病（PD），其产生的健康成本高达100万美元

项目成果

期刊论文数量（3）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Fully Automated Radiosynthesis of [18F]mG4P027 for mGluR4 Imaging.

用于 mGluR4 成像的 [18F]mG4P027 全自动放射合成。

DOI：
10.1002/ird3.25
发表时间：
2023
期刊：
iRadiology
影响因子：
0
作者：
Moon,Sung-Hyun;ElFakhri,Georges;Zhang,Zhaoda;Brownell,Anna-Liisa;Wang,Junfeng
通讯作者：
Wang,Junfeng

A concise method for fully automated radiosyntheses of [18F]JNJ-46356479 and [18F]FITM via Cu-mediated 18F-fluorination of organoboranes.

一种通过有机硼烷的 Cu 介导的 18F 氟化来全自动放射合成 [18F]JNJ-46356479 和 [18F]FITM 的简明方法。

DOI：
10.1039/d0ra04943c
发表时间：
2020
期刊：
RSC advances
影响因子：
3.9
作者：
Yuan,Gengyang;Shoup,TimothyM;Moon,Sung-Hyun;Brownell,Anna-Liisa
通讯作者：
Brownell,Anna-Liisa

Transition Metal-Free Intermolecular C(sp2)-H Direct Amination of Furanones via a Redox Pathway.

DOI：
10.1021/acs.joc.8b02760
发表时间：
2019-01
期刊：
The Journal of organic chemistry
影响因子：
0
作者：
Q. Wei;Junfeng Wang;E. Akam;Dawei Yin;Z. Ge;T. Cheng;Xin Wang;A. Brownell;Runtao Li
通讯作者：
Q. Wei;Junfeng Wang;E. Akam;Dawei Yin;Z. Ge;T. Cheng;Xin Wang;A. Brownell;Runtao Li